|
1) Kushner JP, Porter J, Olivieri N. Secondary iron overload. Journal (Issue), 2001
|
|
|
|
|
2) McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983; 19: 205-66
|
|
|
|
|
3) Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park). 2006; 20: 1799-806, 1811; discussion 1811-1713, 1817
|
|
|
|
|
|
4) Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78: 487-94
|
|
|
|
|
5) 高後 裕. 鉄過剰の診断とモニタリング. In: 堀田知光, 他, 監修. Iron Overloadと鉄キレート療法. 東京: メディカルレビュー社; 2007. p. 145-59
|
|
|
|
|
|
6) Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23: 7594-603
|
|
|
|
|
|
7) Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. ASH 49th Annual Meeting, 2007. Abstract 249
|
|
|
|
|
|
8) Di Tucci AA, Murru R, Alberti D, et al. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007; 78: 540-2
|
|
|
|
|
|
9) Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94: 288-99
|
|
|
|
|
|
10) 小船雅義, 新津洋司郎. 鉄過剰症の病態と診断 総論. In: 堀田知光, 他, 監修. Iron Overloadと鉄キレート療法. 東京: メディカルレビュー社; 2007. p. 107-15
|
|
|
|
|
|
11) Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006; 12: 446-51
|
|
|
|
|
|
12) Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004; 431: 997-1002
|
|
|
|
|
|
13) Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91: 873-80
|
|
|
|
|
|
14) Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006; 107: 3455-62
|
|
|
|
|
|
15) Porter JVE, Rose C, Piga A, et al. A phase 2 study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Blood. 2004; 104: abstract 3193
|
|
|
|
|
|
16) Sergejew T, Forgiarini P, Schnebli HP. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol. 2000; 110: 985-92
|
|
|
|
|
|
17) Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol. 2008; 88: 30-5
|
|
|
|
|
|
18) 小澤敬也. 国内における鉄過剰症の診断と治療のガイドライン. In: 堀田知光, 他, 監修. Iron Overloadと鉄キレート療法. 東京: メディカルレビュー社; 2007. p. 185-9
|
|
|
|
|
|
19) Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008; 88: 24-9
|
|
|
|
|